IDH1 Gene Mutation clinical trials at UC Irvine

1 research study open to eligible people

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
open to eligible people ages 18 years and up
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
Orange, California and other locations

Last updated: March 17, 2026